Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.08 USD | -1.69% | -5.40% | +16.56% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.56% | 5.48B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.67% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- (HALO) HALOZYME THERAPEUTICS Sees Fiscal Year 2024 Revenue Range $915M - $985M